Table 1 Drugs demonstrating significantly increased or decreased activity in HNSCC cell lines compared with non-HNSCC lines
Drug | p* | LFDR** | Drug response relative to other cell lines | Effect(Log2(IC50(μM)) | 95% CI (Log2(IC50(μM))) |
|---|---|---|---|---|---|
Bosutinib | <0.0001 | 0.0015 | Sensitive | -2.74 | (-3.67 to -1.82) |
Docetaxel | <0.0001 | 0.0161 | Sensitive | -2.29 | (-3.17 to -1.42) |
BIBW2992 | 0.0002 | 0.0161 | Sensitive | -3.12 | (-4.53 to -1.71) |
Gefitinib | 0.0003 | 0.0258 | Sensitive | -2.18 | (-3.24 to -1.12) |
PD-173074 | 0.0002 | 0.0183 | Resistance | 0.95 | (0.50-1.40) |
Methotrexate | 0.0005 | 0.0258 | Resistance | 1.59 | (0.77-2.42) |